Systemic immune modulation by stereotactic radiotherapy in early-stage lung cancer

HIGHLIGHTS

• who: Eleni Gkika from the DepartmentUniversity of of Medicine, Freiburg, Germany have published the research: Systemic immune modulation by stereotactic radiotherapy in early-stage lung cancer, in the Journal: (JOURNAL) of 22/07/2022
• what: The study shows that SBRT alone can significantly increase the fraction of proliferating CD4+ and CD8+ circulating Tcells, most prominently at the end of treatment and only in the cohort of early-stage NSCLC who received 10 Gy or less per fraction.
• future: Since no patient received ICB combined with SBRT future studies should determine whether and how . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.